Long-term follow-up of four out of seven patients with severe hemophilia B treated with AAV2-hFIX16 revealed that none of the patients enrolled in a 12–15-year follow-up protocol showed evidence of FIX inhibitors at any point. Here, F9 is linked to hemophilia B.